Voglibose

Oral
Diabetes mellitus

Should be taken with food. Take just before meals.

Inflammatory bowel disease; GI obstruction or patients predisposed to it; conditions which may deteriorate as a result of increased gas formation eg, hernia; severe ketosis; diabetic coma or pre-coma; severe infection; hypersensitivity; pregnancy; lactation. Not to be used as monotherapy in IDDM.

History of laparotomy or ileus. Roemheld's syndrome, stenosis, severe hepatic or renal impairment. Child <18 yr; elderly. Monitor LFT. Treat hypoglycaemic episodes with glucose (not with sucrose).

Flatulence; abdominal distension; diarrhoea; pain; skin reactions; hypoglycemia; increased LFT.
Potentially Fatal: Hepatotoxicity.

May enhance effects of other antidiabetics including insulin.

Description: Voligbose has general properties similar to acarbose and selectively inhibits α-glucosidase in the enteric canal, delaying the digestion and absorption of carbohydrate, thereby suppressing sharp increase in post-prandial plasma glucose.

Store below 30°C.

Antidiabetic Agents